| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/19/2009 | CA2641248A1 Patch preparation |
| 04/19/2009 | CA2607149A1 Predicting responsiveness to cancer therapeutics |
| 04/16/2009 | WO2009049258A1 Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies |
| 04/16/2009 | WO2009049251A1 Novel rna interference methods using dna-rna duplex constructs |
| 04/16/2009 | WO2009049242A1 Autophagy inducing compounds and uses thereof in treating autophagy associated diseases |
| 04/16/2009 | WO2009049239A1 Use of adsorbent carbon microspheres to treat pouchitis |
| 04/16/2009 | WO2009049234A2 Methods of treating coagulopathy |
| 04/16/2009 | WO2009049233A1 Method for treating and/or preventing drug seeking behavior |
| 04/16/2009 | WO2009049214A2 Inhibition and treatment of prostate cancer metastasis |
| 04/16/2009 | WO2009049208A1 Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents |
| 04/16/2009 | WO2009049183A1 Aryl amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | WO2009049181A1 Amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | WO2009049180A2 Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| 04/16/2009 | WO2009049165A1 Novel seh inhibitors and their use |
| 04/16/2009 | WO2009049157A1 Novel seh inhibitors and their use |
| 04/16/2009 | WO2009049154A1 NOVEL sEH INHIBITORS AND THEIR USE |
| 04/16/2009 | WO2009049132A1 Quinoline derivatives for modulating dna methylation |
| 04/16/2009 | WO2009049113A1 Piperidinylhydroxyethylpiperidines as modulators of chemokine receptors |
| 04/16/2009 | WO2009049112A1 Prolyl hydroxylase inhibitors |
| 04/16/2009 | WO2009049111A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 |
| 04/16/2009 | WO2009049109A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2 |
| 04/16/2009 | WO2009049105A2 Methods for inducing satiation |
| 04/16/2009 | WO2009049098A2 Materials and methods for regulating the activity of phosphatases |
| 04/16/2009 | WO2009049086A1 Broad spectrum beta-lactamase inhibitors |
| 04/16/2009 | WO2009049028A1 Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| 04/16/2009 | WO2009049022A1 Method for treatment of pancreatitis |
| 04/16/2009 | WO2009049021A1 Heterocyclic compounds as crth2 receptor antagonists |
| 04/16/2009 | WO2009049018A1 Novel compounds and methods of using them |
| 04/16/2009 | WO2009048993A2 Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators |
| 04/16/2009 | WO2009048980A2 Emp2 antibodies and their therapeutic uses |
| 04/16/2009 | WO2009048967A1 Combination therapy with antibody-drug conjugates |
| 04/16/2009 | WO2009048957A1 Antimalarial compounds with flexible side-chains |
| 04/16/2009 | WO2009048953A1 Thrombopoietin receptor agonist (tpora) kills acute human myeloid leukemia cells |
| 04/16/2009 | WO2009048940A2 Diacerein pharmaceutical formulations |
| 04/16/2009 | WO2009048936A1 Novel compounds as cannabinoid receptor ligands |
| 04/16/2009 | WO2009048932A2 Methods to regulate mirna processing by targeting lin-28 |
| 04/16/2009 | WO2009048924A1 Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents |
| 04/16/2009 | WO2009048868A1 Photodynamic therapy process and photosensitizer compositions |
| 04/16/2009 | WO2009048864A1 Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
| 04/16/2009 | WO2009048848A1 Pharmaceutical formulation of valsartan |
| 04/16/2009 | WO2009048841A1 Antifungal treatment of nails |
| 04/16/2009 | WO2009048778A2 Laminins, derivatives, and compositions including same and method for their therapeutic use |
| 04/16/2009 | WO2009048765A1 5-ht7 receptor antagonists |
| 04/16/2009 | WO2009048760A2 Biphenyl inhibitors of carbonyl reductase |
| 04/16/2009 | WO2009048605A1 Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
| 04/16/2009 | WO2009048603A1 Methods and kits for the treatment of diverticular conditions |
| 04/16/2009 | WO2009048594A2 Multicomponent bioactive intravaginal ring |
| 04/16/2009 | WO2009048590A2 Amino acid combinant omega oil aphrodisiac |
| 04/16/2009 | WO2009048541A2 Compounds and methods for use in treating neoplasia and cancer |
| 04/16/2009 | WO2009048540A1 Method and composition for treating heart failure |
| 04/16/2009 | WO2009048527A1 Substituted biphenyl gpr40 modulators |
| 04/16/2009 | WO2009048521A1 Potentiating the effect of compound comprising nitric oxide |
| 04/16/2009 | WO2009048474A1 2,7,9-substituted purinone derivatives for immunosuppression |
| 04/16/2009 | WO2009048343A1 Functional lipid constructs |
| 04/16/2009 | WO2009048314A1 A scalable matrix for the in vivo cultivation of bone and cartilage |
| 04/16/2009 | WO2009048289A2 Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid |
| 04/16/2009 | WO2009048251A2 Pharmaceutical composition containing micronized particles of naphthoquinone-based compound |
| 04/16/2009 | WO2009048249A2 Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
| 04/16/2009 | WO2009048195A1 Laurinterol compound derived from laurencia okamurai for the prevention and inhibition of melanoma |
| 04/16/2009 | WO2009048192A1 Composition for improving tlr-mediated cellular immunity comprising poly-gamma-glutamic acid |
| 04/16/2009 | WO2009048148A1 Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine |
| 04/16/2009 | WO2009048128A1 Body weight gain inhibitor |
| 04/16/2009 | WO2009048123A1 Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof |
| 04/16/2009 | WO2009048120A1 Water-soluble composition containing astaxanthin |
| 04/16/2009 | WO2009048101A1 Amide compound |
| 04/16/2009 | WO2009048073A1 Method of coating granules |
| 04/16/2009 | WO2009048072A1 ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15 |
| 04/16/2009 | WO2009047935A1 Fine particles |
| 04/16/2009 | WO2009047928A1 Method of producing functional dna, transformant and remedy for disease |
| 04/16/2009 | WO2009047904A1 Therapeutic agent for inflammatory bowel disease comprising uracil derivative as active ingredient |
| 04/16/2009 | WO2009047903A1 Prophylactic or therapeutic agent for inflammatory disease comprising thymidine phosphorylase inhibitor as active ingredient |
| 04/16/2009 | WO2009047826A2 Pharmaceutical composition comprising sucralphate and mesalazine |
| 04/16/2009 | WO2009047802A2 Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof |
| 04/16/2009 | WO2009047801A1 Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
| 04/16/2009 | WO2009047800A2 Oral controlled release composition of carvedilol |
| 04/16/2009 | WO2009047799A1 High dose solid unit oral pharmaceutical dosage form of mycophenolate sodium and process for making same |
| 04/16/2009 | WO2009047798A2 Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| 04/16/2009 | WO2009047788A2 Topical composition containing the combination of mupirocin and beclomethasone |
| 04/16/2009 | WO2009047779A2 Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form |
| 04/16/2009 | WO2009047775A2 Polymorphs of esomeprazole salts |
| 04/16/2009 | WO2009047770A2 Cytoplasmic malate dehydrogenase (mdh1) targeted treatment for neurodegenerative diseases |
| 04/16/2009 | WO2009047754A2 Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation |
| 04/16/2009 | WO2009047752A1 Breast cancer therapy |
| 04/16/2009 | WO2009047723A2 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
| 04/16/2009 | WO2009047644A2 Method of treating vitamin d insufficiency and deficiency |
| 04/16/2009 | WO2009047637A1 Novel polymorphs of bosentan |
| 04/16/2009 | WO2009047634A2 Aqueous formulations of acetaminophen for injection |
| 04/16/2009 | WO2009047633A2 Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate |
| 04/16/2009 | WO2009047618A1 Cosmetic and/or dermatological compositions and use thereof for depigmentation |
| 04/16/2009 | WO2009047563A1 Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
| 04/16/2009 | WO2009047562A1 Methods and compositions for the treatment of pruritus |
| 04/16/2009 | WO2009047558A1 Benzothiazoles as ghrelin receptor modulators |
| 04/16/2009 | WO2009047537A1 Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 04/16/2009 | WO2009047534A2 Fused phenothiazinium compounds, preparation method thereof and use as photoantimicrobials |
| 04/16/2009 | WO2009047522A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | WO2009047506A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | WO2009047505A2 Dexanabinol with inhibitors of braf or mek for the treatment of melanoma |
| 04/16/2009 | WO2009047481A1 Method & composition for the treatment of acne and sebum dependent pilosebaceous disorders |
| 04/16/2009 | WO2009047359A1 Inhibitors of protein kinases |
| 04/16/2009 | WO2009047343A1 Benzocycloheptene derivatives as estrogens having selective activity |